Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver Targeting

Published on Aug 18, 2020in Journal of Medicinal Chemistry6.205
· DOI :10.1021/ACS.JMEDCHEM.0C00640
Kim Huard12
Estimated H-index: 12
Aaron C. Smith12
Estimated H-index: 12
+ 30 AuthorsXiaojing Helen Yang1
Estimated H-index: 1
Preclinical and clinical data suggest that acetyl-CoA carboxylase (ACC) inhibitors have the potential to rebalance disordered lipid metabolism leading to improvements in non-alcoholic steatohepatit...
#1Kenneth L. Kelly (Pfizer)H-Index: 2
#2William J. Reagan (Pfizer)H-Index: 14
Last. William P. Esler (Pfizer)H-Index: 10
view all 23 authors...
Acetyl-CoA carboxylase (ACC) catalyses the first step of de novo lipogenesis (DNL). Pharmacologic inhibition of ACC has been of interest for therapeutic intervention in a wide range of diseases. We demonstrate here that ACC and DNL are essential for platelet production in humans and monkeys, but in not rodents or dogs. During clinical evaluation of a systemically distributed ACC inhibitor, unexpected dose-dependent reductions in platelet count were observed. While platelet count reductions were ...
4 CitationsSource
#1Arthur Bergman (Pfizer)H-Index: 8
#2Santos Carvajal-Gonzalez (Pfizer)H-Index: 10
Last. Neeta B. Amin (Pfizer)H-Index: 7
view all 6 authors...
PF-05221304 is a liver-targeted inhibitor of acetyl-CoA carboxylase, an enzyme that catalyzes the first committed step in de novo lipogenesis (DNL). This first-in-human study investigated safety/tolerability and pharmacokinetics of single and multiple ascending oral PF-05221304 doses, and fructose-stimulated DNL inhibition with repeated oral doses. Healthy subjects (n = 96) received single (1-240 mg) or repeated (2-200 mg daily) doses for 14 days or single 100-mg doses with and without food. PF-...
11 CitationsSource
#1Naim Alkhouri (University of Texas at Austin)H-Index: 46
#1Naim Alkhouri (University of Texas at Austin)H-Index: 5
Last. Gerald I. Shulman (Yale University)H-Index: 182
view all 5 authors...
ABSTRACTIntroduction: De novo lipogenesis (DNL) plays a major role in fatty acid metabolism and contributes significantly to triglyceride accumulation within the hepatocytes in patients with nonalc...
29 CitationsSource
Non-alcoholic steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease (NAFLD) characterized by liver steatosis, inflammation, and hepatocellular damage. NASH is a serious condition that can progress to cirrhosis, liver failure, and hepatocellular carcinoma. The association of NASH with obesity, type 2 diabetes mellitus, and dyslipidemia has led to an emerging picture of NASH as the liver manifestation of metabolic syndrome. Although diet and exercise can dramatically improve...
23 CitationsSource
#1Trenton T. Ross (Pfizer)H-Index: 4
#2Collin Crowley (Pfizer)H-Index: 2
Last. William P. Esler (Pfizer)H-Index: 10
view all 16 authors...
BACKGROUND AND AIMS Disordered metabolism, steatosis, hepatic inflammation, and fibrosis contribute to the pathogenesis of nonalcoholic steatohepatitis (NASH). Acetyl-CoA carboxylase (ACC) catalyzes the first committed step in de novo lipogenesis (DNL) and modulates mitochondrial fatty acid oxidation. Increased hepatic DNL flux and reduced fatty acid oxidation are hypothesized to contribute to steatosis. Some pro-inflammatory cells also show increased dependency on DNL, suggesting that ACC may r...
8 CitationsSource
#1Viera Kupčová (Comenius University in Bratislava)H-Index: 2
#2Michaela Fedelešová (Comenius University in Bratislava)H-Index: 1
Last. Turecký L (Comenius University in Bratislava)H-Index: 6
view all 5 authors...
Nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease worldwide. It represents a range of disorders, including simple steatosis, nonalcoholic steatohepatitis (NASH), and liver cirrhosis, and its prevalence continues to rise. In some cases, hepatocellular carcinoma (HCC) may develop. The develop;ment of non-invasive diagnostic and screening tools is needed, in order to reduce the frequency of liver biopsies. The most promising methods are those able to exclude advan...
19 CitationsSource
#1William P. Esler (Pfizer)H-Index: 10
#2Gregory J. Tesz (Pfizer)H-Index: 5
Last. Gabriele E. Sonnenberg (Pfizer)H-Index: 4
view all 23 authors...
Sebum plays important physiological roles in human skin. Excess sebum production contributes to the pathogenesis of acne vulgaris, and suppression of sebum production reduces acne incidence and severity. We demonstrate that sebum production in humans depends on local flux through the de novo lipogenesis (DNL) pathway within the sebocyte. About 80 to 85% of sebum palmitate (16:0) and sapienate (16:1n10) were derived from DNL, based on stable isotope labeling, much higher than the contribution of ...
16 CitationsSource
#1James S. V. Lally (McMaster University)H-Index: 14
#2Sarani Ghoshal (Harvard University)H-Index: 11
Last. Bryan C. Fuchs (Harvard University)H-Index: 33
view all 35 authors...
Summary The incidence of hepatocellular carcinoma (HCC) is rapidly increasing due to the prevalence of obesity and non-alcoholic fatty liver disease, but the molecular triggers that initiate disease development are not fully understood. We demonstrate that mice with targeted loss-of-function point mutations within the AMP-activated protein kinase (AMPK) phosphorylation sites on acetyl-CoA carboxylase 1 (ACC1 Ser79Ala) and ACC2 (ACC2 Ser212Ala) have increased liver de novo lipogenesis (DNL) and l...
79 CitationsSource
#1Emi Kimoto (Pfizer)H-Index: 23
#2Manoli Vourvahis (Pfizer)H-Index: 15
Last. Manthena V.S. Varma (Pfizer)H-Index: 38
view all 6 authors...
The aim of the present study was to quantitatively evaluate the drug-drug interactions (DDIs) of maraviroc (MVC) with various perpetrator drugs, including telaprevir (TVR), using an in vitro data-informed physiologically based pharmacokinetic (PBPK) model. MVC showed significant active uptake and biliary excretion in sandwich-cultured human hepatocytes, and biphasic organic anion transporting polypeptide (OATP)1B1-mediated uptake kinetics in transfected cells (high-affinity Km ∼5 µM). No measure...
9 CitationsSource
#1Leigh Goedeke (Yale University)H-Index: 25
#2J. BatesH-Index: 5
Last. Gerald I. Shulman (Yale University)H-Index: 182
view all 14 authors...
: Pharmacologic inhibition of acetyl-CoA carboxylase (ACC) enzymes, ACC1 and ACC2, offers an attractive therapeutic strategy for nonalcoholic fatty liver disease (NAFLD) through simultaneous inhibition of fatty acid synthesis and stimulation of fatty acid oxidation. However, the effects of ACC inhibition on hepatic mitochondrial oxidation, anaplerosis, and ketogenesis in vivo are unknown. Here, we evaluated the effect of a liver-directed allosteric inhibitor of ACC1 and ACC2 (Compound 1) on thes...
86 CitationsSource
Cited By2
Last. Michael KeeseH-Index: 21
view all 6 authors...
Abdominal aortic aneurysm (AAA) is a prevalent aortic disease that causes high mortality due to asymptomatic gradual expansion and sudden rupture. The underlying molecular mechanisms and effective pharmaceutical therapy for preventing AAA progression have not been fully identified. In this study, we identified the key modules and hub genes involved in AAA growth from the GSE17901 dataset in the Gene Expression Omnibus (GEO) database through the weighted gene co-expression network analysis (WGCNA...
#1Raj Vuppalanchi (IU: Indiana University)H-Index: 43
#2Mazen Noureddin (Cedars-Sinai Medical Center)H-Index: 25
Last. Arun J. Sanyal (VCU: Virginia Commonwealth University)H-Index: 121
view all 4 authors...
Our understanding of nonalcoholic fatty liver disease pathophysiology continues to advance rapidly. Accordingly, the field has moved from describing the clinical phenotype through the presence of nonalcoholic steatohepatitis (NASH) and degree of fibrosis to deep phenotyping with a description of associated comorbidities, genetic polymorphisms and environmental influences that could be associated with disease progression. These insights have fuelled a robust therapeutic pipeline across a variety ...
9 CitationsSource